Neovaxsyn Inc.
Ames, IA Doing business as Neovaxsyn Inc.
- UEI
- EHMTBALCKFE8
- CAGE
- 7RK00
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4140 Cochrane Pkwy, Ames, IA 50014, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A novel strategy for the next generation raav gene therapy and vaccine vector production - project summary/abstract… | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Development of a next-generation immunoprevention platform against HIV-1 | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Nanovaccine for eliciting bnabs against HIV-1 | National Institute of Allergy and Infectious Diseases | $2,000,000 | |
| Induction of bnabs against HIV-1 GP41. - project summary/abstract despite the availability of effective… | National Institute of Mental Health | $894,624 | |
| Sbir phase i | National Institute of Allergy and Infectious Diseases | $300,000 |
About Neovaxsyn Inc.
Neovaxsyn Inc. is a minority-owned, self-certified small disadvantaged business located in Ames, Iowa, specializing in biotechnology research and development with a focused expertise in HIV/AIDS vaccine technologies. The company provides innovative research services to federal agencies, particularly within the biomedical and infectious disease domains, leveraging advanced nanotechnology and immunological approaches to develop potential medical countermeasures. As a registered federal government contractor and grant recipient, Neovaxsyn Inc. has demonstrated a strategic commitment to advancing vaccine research through sophisticated scientific methodologies.
Neovaxsyn Inc. has secured multiple federal contract awards from the National Institute of Allergy and Infectious Diseases (NIAID), all designated as total small business set-asides under the Small Business Innovation Research (SBIR) program. These contracts, ranging from $300,000 to $2,000,000, focus explicitly on developing next-generation immunoprevention platforms against HIV-1. The company's contract work involves complex research initiatives utilizing nanoparticle technologies to deliver vaccine components, with specific objectives including eliciting broadly neutralizing antibodies (BNABs) against HIV-1. The contracts span various research phases, including Phase I and Phase II SBIR programs, and involve innovative approaches such as using gold nanoparticles and developing nanovaccine strategies to target specific viral proteins like GP41.
In terms of federal grant awards, Neovaxsyn Inc. has received at least one significant grant from the National Institute of Mental Health, specifically a Phase I SBIR grant (R43MH133248) focused on inducing broadly neutralizing antibodies against HIV-1 GP41. The grant, valued at an undisclosed amount and spanning from September 2022 to August 2024, aims to evaluate a novel "antibody-stabilized, epitope presentation" (ASEP) vaccine strategy. The grant's primary objective is to demonstrate the feasibility of using specific immune complexes as immunogens to potentially develop a protective AIDS vaccine, with a particular focus on generating 10E8-like antibodies that could neutralize a wide range of HIV-1 isolates.
Quick answers
What is Neovaxsyn Inc.'s UEI?
Neovaxsyn Inc.'s Unique Entity ID (UEI) in SAM.gov is EHMTBALCKFE8.
What is Neovaxsyn Inc.'s CAGE code?
Neovaxsyn Inc.'s CAGE code is 7RK00.
What is Neovaxsyn Inc.'s primary NAICS code?
Neovaxsyn Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Neovaxsyn Inc. located?
Neovaxsyn Inc.'s physical address in SAM.gov is 4140 Cochrane Pkwy, Ames, IA 50014, USA.
Is Neovaxsyn Inc. registered in SAM.gov?
Yes. Neovaxsyn Inc.'s SAM.gov registration is active through December 13, 2026.
What is Neovaxsyn Inc.'s most recent federal award?
Neovaxsyn Inc.'s most recent federal grant award is A novel strategy for the next generation raav gene therapy and vaccine vector production - project summary/abstract… (R43AI197694), from National Institute of Allergy and Infectious Diseases, on September 1, 2026.
On GovTribe
See Neovaxsyn Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors